Cost–effectiveness of raltegravir in HIV/AIDS

References

• Freedberg KA, Losina E, Weinstein MC et al. The cost effectiveness of combination antiretroviral therapy for HIV disease. N. Engl. J. Med.344(11), 824–831 (2001).
   PubMed Web of Science ®Google Scholar
• Nunes EP, de Oliveira MS, Grinsztejn B. Clinical use of raltegravir: a review. HIV Therap.4(5), 531–542 (2010).
   Google Scholar
• Steigbigel RT, Cooper DA, Kumar PN et al. Raltegravir with optimized background therapy for resistant HIV-1 infection. N. Engl. J. Med.359(4), 339–354 (2008).
   PubMed Web of Science ®Google Scholar
• Cooper DA, Steigbigel RT, Gatell JM et al. Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection. N. Engl. J. Med.359(4), 355–365 (2008).
   PubMed Web of Science ®Google Scholar
• Steigbigel RT, Cooper DA, Teppler H et al. Long-term efficacy and safety of raltegravir combined with optimized background therapy in treatment-experienced patients with drug-resistant HIV infection: week 96 results of the BENCHMRK 1 and 2 Phase III trials. Clin. Infect. Dis.50(4), 605–612 (2010).
   PubMed Web of Science ®Google Scholar
• Gatell JM, Katlama C, Grinsztejn B et al. Long-term efficacy and safety of the HIV integrase inhibitor raltegravir in patients with limited treatment options in a Phase II study. J. Acquir. Immun. Defic. Syndr.53(4), 456–463 (2010).
   PubMed Web of Science ®Google Scholar
• Eron J, Cooper D, Steigbigel R et al. Exploratory analysis in the BENCHMRK studies at week 192: late outcomes based on early virologic responses. Program and Abstracts of the 6th International AIDS Society. Rome, Italy (2011) (Abstract MOPE225).
   Google Scholar
• Markowitz M, Nguyen BY, Gotuzzo E et al. Rapid and durable antiretroviral effect of the HIV-1 integrase inhibitor raltegravir as part of combination therapy in treatment-naive patients with HIV-1 infection: results of a 48-week controlled study. J. Acquir. Immun. Defic. Syndr.46(2), 125–133 (2007).
   PubMed Web of Science ®Google Scholar
• Lennox JL, DeJesus E, Lazzarin A et al. Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial. Lancet374(9692), 796–806 (2009).
   PubMed Web of Science ®Google Scholar
• Lennox JL, DeJesus E, Berger DS et al. Raltegravir versus efavirenz regimens in treatment-naive HIV-1-infected patients: 96-week efficacy, durability, subgroup, safety, and metabolic analyses. J. Acquir. Immun. Defic. Syndr.55(1), 39–48 (2010).
   PubMed Web of Science ®Google Scholar
• Markowitz M, Nguyen BY, Gotuzzo E et al. Sustained antiretroviral effect of raltegravir after 96 weeks of combination therapy in treatment-naive patients with HIV-1 infection. J. Acquir. Immun. Defic. Syndr.52(3), 350–356 (2009).
   PubMed Web of Science ®Google Scholar
• Rockstroh J, Lennox J, DeJesus E et al. Raltegravir demonstrates durable virologic suppression and superior immunologic response with a favorable metabolic profile through 3 years of treatment: 156 week results from STARTMRK. Presented at: 18th Conference on Retroviruses and Opportunistic Infections. 27 February–2 March 2011 Boston, MA, USA (2011).
   Google Scholar
• Teppler H, Brown D, Leavitt Y et al. Long-term safety from the raltegravir clinical development program. Curr. HIV Res.9(1), 40–53 (2011).
   PubMed Web of Science ®Google Scholar
• Levy AR, James D, Johnston KM et al. The direct costs of HIV/AIDS care. Lancet Infect. Dis.6(3), 171–177 (2006).
   PubMed Web of Science ®Google Scholar
• Gardner EM, Maravi ME, Rietmeijer C, Davidson AJ, Burman WJ. The association of adherence to antiretroviral therapy with healthcare utilization and costs for medical care. Appl. Health Econ. Health Policy6(2–3), 145–155 (2008).
   PubMedGoogle Scholar
• Mandalia S, Mandalia R, Lo G et al. Rising population cost for treating people living with HIV in the UK, 1997–2013. PloS One5(12), e15677 (2010).
   PubMed Web of Science ®Google Scholar
• Gebo KA, Fleishman JA, Conviser R et al. Contemporary costs of HIV healthcare in the HAART era. AIDS24(17), 2705–2715 (2010).
   PubMed Web of Science ®Google Scholar
• Hutchinson AB, Farnham PG, Dean HD et al. The economic burden of HIV in the United States in the era of highly active antiretroviral therapy: evidence of continuing racial and ethnic differences. J. Acquir. Immune Defic. Syndr.43(4), 451–457 (2006).
   PubMedGoogle Scholar
• Liu GG, Guo JJ, Smith SR. Economic costs to business of the HIV/AIDS epidemic. Pharmacoeconomics22(18), 1181–1194 (2004).
   PubMed Web of Science ®Google Scholar
• Croxtall JD, Scott LJ. Raltegravir: in treatment-naive patients with HIV-1 infection. Drugs70(5), 631–642 (2010).
   PubMed Web of Science ®Google Scholar
• Burger DM. Raltegravir: a review of its pharmacokinetics, pharmacology and clinical studies. Expert Opin. Drug Metab. Toxicol.6(9), 1151–1160 (2010).
   PubMed Web of Science ®Google Scholar
• Nguyen BYT, Isaacs RD, Teppler H et al. Raltegravir: the first HIV 1 integrase strand transfer inhibitor in the HIV armamentarium. Ann. NY Acad. Sci.1222(1), 83–89 (2011).
   PubMed Web of Science ®Google Scholar
• Eron J, Young B, Cooper D et al. Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomised controlled trials. Lancet375(9712), 396–407 (2010).
   PubMed Web of Science ®Google Scholar
• Martinez E, Larrousse M, Llibre JM et al. Substitution of raltegravir for ritonavir-boosted protease inhibitors in HIV-infected patients: the SPIRAL study. AIDS24(11), 1697–1707 (2010).
   PubMed Web of Science ®Google Scholar
• Marcelin AG, Ceccherini-Silberstein F, Perno CF, Calvez V. Resistance to novel drug classes. Curr. Opin HIV AIDS4(6), 531–537 (2009).
   PubMed Web of Science ®Google Scholar
• Rosenblum M, Deeks SG, Van Der Laan M, Bangsberg DR. The risk of virologic failure decreases with duration of HIV suppression, at greater than 50% adherence to antiretroviral therapy. PloS One4(9), e7196 (2009).
   PubMed Web of Science ®Google Scholar
• Reekie J, Mocroft A, Ledergerber B et al. History of viral suppression on combination antiretroviral therapy as a predictor of virological failure after a treatment change. HIV Med.11(7), 469–478 (2010).
   PubMedGoogle Scholar
• Harris M, Larsen G, Montaner JSG. Outcomes of multidrug-resistant patients switched from enfuvirtide to raltegravir within a virologically suppressive regimen. AIDS22(10), 1224–1226 (2008).
   PubMed Web of Science ®Google Scholar
• Towner W, Klein D, Kerrigan HL, Follansbee S, Yu K, Horberg M. Virologic outcomes of changing enfuvirtide to raltegravir in HIV-1 patients well controlled on an enfuvirtide based regimen: 24-week results of the CHEER study. J. Acquir. Immun. Defic. Syndr.51(4), 367–373 (2009).
   PubMed Web of Science ®Google Scholar
• Boulet T, Pavie J, Charreau I et al. Impact on health-related quality of life of a switch from enfuvirtide to raltegravir among multidrug-resistant HIV-1-infected patients: a randomized open-label trial (EASIER-ANRS 138). HIV Clin. Trial.11(5), 283–293 (2010).
   PubMed Web of Science ®Google Scholar
• Nguyen A, Calmy A, Delhumeau C et al. A randomized cross-over study to compare raltegravir and efavirenz (SWITCH-ER study). AIDS25(12), 1481–1487 (2011).
   PubMed Web of Science ®Google Scholar
• Fransen S, Gupta S, Danovich R et al. Loss of raltegravir susceptibility by human immunodeficiency virus type 1 is conferred via multiple nonoverlapping genetic pathways. J. Virol.83(22), 11440–11446 (2009).
   PubMed Web of Science ®Google Scholar
• Hu Z, Kuritzkes DR. Effect of raltegravir resistance mutations in HIV-1 integrase on viral fitness. J. Acquir. Immun. Defic. Syndr.55(2), 148–155 (2010).
   PubMed Web of Science ®Google Scholar
• Wirden M, Simon A, Schneider L et al. Raltegravir has no residual antiviral activity in vivo against HIV-1 with resistance-associated mutations to this drug. J. Antimicrob. Chemother.64(5), 1087–1090 (2009).
   PubMed Web of Science ®Google Scholar
• Weinstein MC, Siegel JE, Gold MR, Kamlet MS, Russell LB. Recommendations of the panel on cost–effectiveness in health and medicine. JAMA276(15), 1253–1258 (1996).
   PubMed Web of Science ®Google Scholar
• Devlin N, Parkin D. Does NICE have a cost effectiveness threshold and what other factors influence its decisions? A binary choice analysis. Health Econ.13(5), 437–452 (2004).
   PubMed Web of Science ®Google Scholar
• Chaudhary MA, Moreno S, Kumar RN, Nocea G, Elbasha E. Cost–effectiveness analysis of raltegravir in treatment-experienced HIV type 1-infected patients in Spain. AIDS Res. Hum. Retrovir.25(7), 679–689 (2009).
   PubMedGoogle Scholar
• Elbasha E, Szucs T, Chaudhary M et al. Cost–effectiveness of raltegravir in antiretroviral treatment-experienced HIV-1-infected patients in Switzerland. HIV Clin. Trials10(4), 233–253 (2009).
   PubMed Web of Science ®Google Scholar
• Elbasha E, Dunlop W, Chaudhary M, Kumar R. An economic evaluation of using raltegravir in treatment-experienced HIV-1 infected patients in the UK. J. Int. AIDS Soc.11(Suppl. 1), P310 (2008).
   Google Scholar
• Ledergerber B, Lundgren J, Walker A et al. PLATO Collaboration. Predictors of trend in CD4-positive T-cell count and mortality among HIV-1-infected individuals with virological failure to all three antiretroviral-drug classes. Lancet364(9428), 51–62 (2004).
   PubMed Web of Science ®Google Scholar
• Weinstein MC, Goldie SJ, Losina E et al. Use of genotypic resistance testing to guide HIV therapy: clinical impact and cost–effectiveness. Ann. Intern. Med.134(6), 440–450 (2001).
   PubMed Web of Science ®Google Scholar
• Phillips A, Ledergerber B, Horban A et al. Rate of viral rebound according to specific drugs in the regimen in 2120 patients with HIV suppression. AIDS18(13), 1795–1804 (2004).
   PubMedGoogle Scholar
• Mocroft A, Ledergerber B, Katlama C et al. Decline in the AIDS and death rates in the EuroSIDA study: an observational study. Lancet362(9377), 22–29 (2003).
   PubMed Web of Science ®Google Scholar
• Olsen C, Gatell J, Ledergerber B et al. Risk of AIDS and death at given HIV-RNA and CD4 cell count, in relation to specific antiretroviral drugs in the regimen. AIDS19(3), 319–330 (2005).
   PubMed Web of Science ®Google Scholar
• Moore RD, Chaisson RE. Natural history of opportunistic disease in an HIV-infected urban clinical cohort. Ann. Intern. Med.124(7), 633–642 (1996).
   PubMed Web of Science ®Google Scholar
• Chaisson RE, Gallant JE, Keruly JC, Moore RD. Impact of opportunistic disease on survival in patients with HIV infection. AIDS12(1), 29–33 (1998).
   PubMed Web of Science ®Google Scholar
• Wohl AR, Lu S, Rollins JN, Simon PA, Grosser S, Kerndt PR. Comparison of AIDS progression and survival in persons with pulmonary versus extrapulmonary tuberculosis in Los Angeles. AIDS Patient Care STDS15(9), 463–471 (2001).
   PubMedGoogle Scholar
• Dolan P. Modeling valuations for EuroQol health states. Med. Care35(11), 1095–1108 (1997).
   PubMed Web of Science ®Google Scholar
• Simpson KN, Luo MP, Chumney E, Sun E, Brun S, Ashraf T. Cost–effectiveness of lopinavir/ritonavir versus nelfinavir as the first-line highly active antiretroviral therapy regimen for HIV infection. HIV Clin. Trials5(5), 294–304 (2004).
   PubMed Web of Science ®Google Scholar
• Freedberg K, Scharfstein J, Seage III G et al. The cost–effectiveness of preventing AIDS-related opportunistic infections. JAMA279(2), 130–136 (1998).
   PubMed Web of Science ®Google Scholar
• Schackman B, Goldie S, Freedberg K, Losina E, Brazier J, Weinstein M. Comparison of health state utilities using community and patient preference weights derived from a survey of patients with HIV/AIDS. Med. Decis. Making22(1), 27–38 (2002).
   PubMed Web of Science ®Google Scholar
• Stavem K, Frøland S, Hellum K. Comparison of preference-based utilities of the 15D, EQ-5D and SF-6D in patients with HIV/AIDS. Qual. Life Res.14(4), 971–980 (2005).
   PubMed Web of Science ®Google Scholar
• Druyts E, Yip B, Lima V et al. Health care services utilization stratified by virological and immunological markers of HIV: evidence from a universal health care setting. HIV Med.10(2), 88–93 (2009).
   PubMed Web of Science ®Google Scholar
• Simcock M, Sendi P, Ledergerber B et al. A longitudinal analysis of healthcare costs after treatment optimization following genotypic antiretroviral resistance testing: does resistance testing pay off? Antivir. Ther.11(3), 305–314 (2006).
   PubMedGoogle Scholar
• Sendi P, Günthard HF, Simcock M, Ledergerber B, Schüpbach J, Battegay M. Cost–effectiveness of genotypic antiretroviral resistance testing in HIV-infected patients with treatment failure. PloS One2(1), e173 (2007).
   PubMed Web of Science ®Google Scholar
• Erdesz D, Nagy L, Brandtmuller A et al. PN52 an economic evaluation of raltegravir for the treatment of antiretroviral-naive HIV-1 infected patients in Hungary. Value Health13(7), A439 (2010).
   Google Scholar
• Chaudhary MA, Elbasha EE, Pereira R, Kumar RN. PN34 a continuous time economic model to evaluate raltegravir use strategies in treatment-naive HIV-1 patients in Portugal. Value Health13(7), A436 (2010).
   Google Scholar
• Chaudhary M, Elbasha E, Kumar R, Lundberg J. PIN33 cost-utility analysis of raltegravir in HIV-infected treatment naive patients in Sweden. Value Health14(3), A119–A119 (2011).
   Google Scholar
• Tilden D, Jackson D, LeReun C et al. A modelled economic evaluation of raltegravir compared with standard practice in Australia for treatment naive patients with HIV. Value Health13(7), A550 (2010).
   Google Scholar
• Kalbfleisch JD, Lawless JF. The analysis of panel data under a Markov assumption. J. Am. Stat. Assoc.80, 863–871 (1985).
   Web of Science ®Google Scholar
• Jackson C. Multi-state modeling with R: the msm package, version 0.7.6. The R Foundation for Statistical Computing, Vienna, Austria (2009).
   Google Scholar
• Phillips A, Pezzotti P. Short-term risk of AIDS according to current CD4 cell count and viral load in antiretroviral drug-naive individuals and those treated in the monotherapy era. AIDS18(1), 51–58 (2004).
   PubMed Web of Science ®Google Scholar
• Pletcher S. Model fitting and hypothesis testing for age-specific mortality data. J. Evolut. Biol.12(3), 430–439 (1999).
   Web of Science ®Google Scholar
• Bokov AF, Gelfond J. Survomatic, package for the analysis of longivity data in R, a programming environment for data analysis and graphics, Version 2.10.1 (2009-2012-14) (2010).
   Google Scholar
• Dunn D, Woodburn P, Duong T et al. Current CD4 cell count and the short-term risk of AIDS and death before the availability of effective antiretroviral therapy in HIV-infected children and adults. J. Infect. Dis.197(3), 398–404 (2008).
   PubMed Web of Science ®Google Scholar
• Hall H, McDavid K, Ling Q, Sloggett A. Determinants of progression to AIDS or death after HIV diagnosis, United States, 1996 to 2001. Ann. Epidemiol.16(11), 824–833 (2006).
   PubMed Web of Science ®Google Scholar
• Caro J, Ishak K, Migliaccio-Walle K. Estimating survival for cost–effectiveness analyses: a case study in atherothrombosis. Value Health7(5), 627–635 (2004).
   PubMed Web of Science ®Google Scholar
• Wilson PWF, D’Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation97(18), 1837–1847 (1998).
   PubMed Web of Science ®Google Scholar
• Castiel D, Herve C, Gaillard M, Bollaert J, Soula M. Cost–utility analysis of early thrombolytic therapy. Pharmacoeconomics1(6), 438–442 (1992).
   PubMedGoogle Scholar
• Kauf T, Roskell N, Shearer A et al. A predictive model of health state utilities for HIV patients in the modern era of highly active antiretroviral therapy. Value Health11(7), 1144–1153 (2008).
   PubMed Web of Science ®Google Scholar
• LeReun C, Tilden D, Harvey C, Price B, van Bavel J. PIN9 efficacy and safety of raltegravir in treatment naive HIV+ patients: a mixed treatment comparison approach. Presented at: ISPOR 4th Asia-Pacific Conference. 5–7 September, Phuket, Thailand (2010).
   Google Scholar
• Simpson KN, Luo MP, Chumney EC, King MS, Brun S. Cost–effectiveness of lopinavir/ritonavir compared with atazanavir in antiretroviral-naive patients: modelling the combined effects of HIV and heart disease. Clin. Drug Investig.27(1), 67–74 (2007).
   PubMed Web of Science ®Google Scholar